Viridian Therapeutics Income Statement 2025-2011 | VRDN

Brief overview of revenue and earnings at Viridian Therapeutics

The figures are compared over a five-year interval. Revenue reported by Viridian Therapeutics was 1.1 million dollars at the beginning of the period and 70.8 million dollars at the end. Overall revenue changed by +6647.5%, equal to an annualized rate of about 132.2%. The company expanded its revenue base at a high speed.

EBITDA changed from −$40.3 million to −$363 million (−801%). The operating result developed less favorably than sales. EBITDA margin was −3836.2% at the start and −512.3% at the end. A wider margin confirms stronger operating efficiency.

Across the five years, the net result shifted from −$111 million to −$343 million. The loss widened and increased the financial risk.

Over the period, capitalization shifted from 70.1 million dollars to 3 billion dollars (+4165.7%). The valuation did not keep pace with the reported progress.

Summary assessment

The results present an uneven picture without one dominant signal. The constructive conclusion rests on revenue expansion and positive operating leverage. Caution is warranted because of a low EBITDA margin and a weaker final result. The key question is whether sales can be converted into sustainable profit.